Triclaben 10% Oral Suspension for Cattle

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Ingredientes activos:

Triclabendazole

Disponible desde:

Chanelle Pharmaceuticals Manufacturing Limited

Código ATC:

QP52AC

Designación común internacional (DCI):

Triclabendazole

Dosis:

10 percent

formulario farmacéutico:

Oral suspension

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Grupo terapéutico:

Cattle

Área terapéutica:

Benzimidazoles and related substances

indicaciones terapéuticas:

Endoparasiticide

Estado de Autorización:

Authorised

Fecha de autorización:

2002-12-06

Ficha técnica

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Triclaben 10% Oral Suspension for Cattle
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Oral suspension.
Description: An aqueous pink-coloured suspension.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Triclaben 10% is indicated for the treatment of fasciolosis in cattle
caused by early immature, immature and adult
stages of liverfluke (_Fasciola hepatica)_ susceptible to
triclabendazole.
4.3 CONTRAINDICATIONS
Do not use in cases of known hypersensitivity to the active
ingredient.
Each ml contains
ACTIVE SUBSTANCE:
Triclabendazole
100mg
EXCIPIENT(S):
Methyl Parahydroxybenzoate (E218)
2.0 mg
Propyl Parahydroxybenzoate (E216)
0.2 mg
Carmoisine supra (E122).
22.5 micrograms
For a full list of excipients, see section 6.1
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_8_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_4_
_1_
_5_
_9_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Care should be taken to avoid the following practices, because they
increase the risk of development of resistance and
could ultimately result in ineffective therapy:
•
Too frequent and repeated use of anthelmintics from the same class,
over an extended period of time.
•
Under dosing, which may be due to under estimation of body weight,
misadministration of the product or lack of
calibr